148 related articles for article (PubMed ID: 36732054)
21. Discrepant salivary gland response after radioiodine and MIBG therapies.
Jentzen W; Richter M; Poeppel TD; Schmitz J; Brandau W; Bockisch A; Binse I
Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):331-339. PubMed ID: 25566809
[TBL] [Abstract][Full Text] [Related]
22. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
23. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and treatment of neuroblastoma using metaiodobenzylguanidine.
Edeling CJ; Frederiksen PB; Kamper J; Jeppesen P
Clin Nucl Med; 1987 Aug; 12(8):632-7. PubMed ID: 3665302
[TBL] [Abstract][Full Text] [Related]
25. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
[TBL] [Abstract][Full Text] [Related]
26. [Nuclear medicine diagnosis and treatment in pheochromocytoma and neuroblastoma].
Fischer M
Bildgebung; 1987-1989; 56(4):141-5. PubMed ID: 3271589
[TBL] [Abstract][Full Text] [Related]
27. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
28. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography.
Ott RJ; Tait D; Flower MA; Babich JW; Lambrecht RM
Br J Radiol; 1992 Sep; 65(777):787-91. PubMed ID: 1393416
[TBL] [Abstract][Full Text] [Related]
29. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
Lam MG; Lips CJ; Jager PL; Dullaart RP; Lentjes EG; van Rijk PP; de Klerk JM
J Clin Endocrinol Metab; 2005 Oct; 90(10):5888-95. PubMed ID: 16046591
[TBL] [Abstract][Full Text] [Related]
30. Current concepts on the diagnostic use of MIBG in children.
Shulkin BL; Shapiro B
J Nucl Med; 1998 Apr; 39(4):679-88. PubMed ID: 9544682
[TBL] [Abstract][Full Text] [Related]
31. Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.
Huang SY; Bolch WE; Lee C; Van Brocklin HF; Pampaloni MH; Hawkins RA; Sznewajs A; DuBois SG; Matthay KK; Seo Y
Mol Imaging Biol; 2015 Apr; 17(2):284-94. PubMed ID: 25145966
[TBL] [Abstract][Full Text] [Related]
32. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
Gedik GK; Hoefnagel CA; Bais E; Olmos RA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Performance of
Weber M; Schmitz J; Maric I; Pabst K; Umutlu L; Walz M; Herrmann K; Rischpler C; Weber F; Jentzen W; Theurer S; Poeppel TD; Unger N; Fendler WP
J Nucl Med; 2022 Jun; 63(6):869-874. PubMed ID: 34556526
[No Abstract] [Full Text] [Related]
34. The current status of radioiodinated metaiodobenzylguanidine therapy of neuro-endocrine tumors.
Shapiro B; Sisson JC; Shulkin BL; Gross MD; Zempel S
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):55-7. PubMed ID: 9002750
[TBL] [Abstract][Full Text] [Related]
35. 131I-meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma.
Voûte PA; Hoefnagel CA; de Kraker J
Bull Cancer; 1988; 75(1):107-11. PubMed ID: 3359053
[TBL] [Abstract][Full Text] [Related]
36. [Therapeutic effectiveness of 131I-MIBG on malignant pheochromocytoma--results of long-term follow-up].
Kusakabe K; Kanaya K; Kanaya S; Yazaki E; Nakano K; Matsumoto N; Kobayashi H; Maki M; Itou Y; Obara T
Kaku Igaku; 1994 Dec; 31(12):1495-502. PubMed ID: 7861648
[TBL] [Abstract][Full Text] [Related]
37. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
[TBL] [Abstract][Full Text] [Related]
38. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
39. [
Pauwels E; Celen S; Baete K; Koole M; Bechter O; Bex M; Renard M; Clement PM; Jentjens S; Serdons K; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1134-1145. PubMed ID: 36435928
[TBL] [Abstract][Full Text] [Related]
40. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK
Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
